Literature DB >> 9374335

Benzodiazepine receptors in chronic cerebrovascular disease: comparison with blood flow and metabolism.

M Sasaki1, Y Ichiya, Y Kuwabara, T Yoshida, T Fukumura, K Masuda.   

Abstract

UNLABELLED: The brain benzodiazepine (BZD) receptor distribution in patients with chronic cerebrovascular disease was assessed with 123I-iomazenil (IMZ) SPECT, and the findings were compared with the data for the cerebral blood flow (CBF) and cerebral metabolism.
METHODS: We examined nine patients with chronic cerebrovascular diseases, six patients with cerebral infarction and three with moyamoya disease. Iodine-123-IMZ SPECT images were obtained for 15 min, 3 hr after the administration of 167 or 222 MBq 123I-IMZ. In seven patients, the CBF and oxygen metabolism were measured by the 50 steady-state method. In two patients, the CBF and glucose metabolism were measured by 99mTc-HMPAO SPECT and 18F-fluoro-2-deoxy-D-glucose-PET, respectively. The brain was initially classified into 18 regions, and abnormalities in the BZD receptor distribution, CBF and cerebral metabolism were visually evaluated. The count ratio of lesion-to-contralateral normal region (L-to-C ratio) was then used for comparison.
RESULTS: In the core of the infarct, the 123I-IMZ uptake decreased (L-to-C ratios of the blood flow 0.42 +/- 0.26; metabolism 0.45 +/- 0.24; and 123I-IMZ uptake 0.46 +/- 0.14). In the peri-infarct region, the 123I-IMZ uptake slightly decreased (L-to-C ratios of 0.81, 0.82 and 0.89, respectively). In the region of misery perfusion, the 123I-IMZ uptake was preserved (L-to-C ratios of 0.73, 1.07 and 1.02, respectively). In the remote deafferentiated areas in the ipsilateral cerebrum, the 123I-IMZ uptake was preserved (L-to-C ratios of 0.76 +/- 0.10, 0.75 +/- 0.04 and 0.98 +/- 0.05, respectively). In the remote areas in the contralateral cerebellum, the 123I-IMZ uptake was preserved (L-to-C ratios of 0.84 +/- 0.08, 0.85 +/- 0.04 and 0.94 +/- 0.05, respectively).
CONCLUSION: The BZD receptor distribution, as measured by 123I-IMZ SPECT, is not considered to reflect neuronal function, but it may reflect neuronal cell viability. Iodine-123-IMZ SPECT may, therefore, hold promise as a potential probe for neuronal damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9374335

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  5 in total

1.  Atrophy of the corpus callosum associated with a decrease in cortical benzodiazepine receptor in large cerebral arterial occlusive diseases.

Authors:  H Yamauchi; H Fukuyama; Y Dong; H Nabatame; Y Nagahama; S Nishizawa; J Konishi; H Shio
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

2.  Assessing neuronal density in peri-infarct cortex with PET: Effects of cortical topology and partial volume correction.

Authors:  Thomas Funck; Mohammed Al-Kuwaiti; Claude Lepage; Peter Zepper; Jeffrey Minuk; Hyman M Schipper; Alan C Evans; Alexander Thiel
Journal:  Hum Brain Mapp       Date:  2016-09-10       Impact factor: 5.038

3.  Intracerebral Transplantation of Mesenchymal Stromal Cell Compounded with Recombinant Peptide Scaffold against Chronic Intracerebral Hemorrhage Model.

Authors:  Soichiro Takamiya; Masahito Kawabori; Tsukasa Kitahashi; Kentaro Nakamura; Yuki Mizuno; Hironobu Yasui; Yuji Kuge; Aki Tanimori; Yasuyuki Takamatsu; Kohei Yuyama; Hideo Shichinohe; Miki Fujimura
Journal:  Stem Cells Int       Date:  2022-07-31       Impact factor: 5.131

4.  Identifying Dysfunctional Cortex: Dissociable Effects of Stroke and Aging on Resting State Dynamics in MEG and fMRI.

Authors:  Aneta Kielar; Tiffany Deschamps; Ron K O Chu; Regina Jokel; Yasha B Khatamian; Jean J Chen; Jed A Meltzer
Journal:  Front Aging Neurosci       Date:  2016-03-03       Impact factor: 5.750

Review 5.  Selective neuronal loss in ischemic stroke and cerebrovascular disease.

Authors:  Jean-Claude Baron; Hiroshi Yamauchi; Masayuki Fujioka; Matthias Endres
Journal:  J Cereb Blood Flow Metab       Date:  2013-11-06       Impact factor: 6.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.